About
About Pieris Pharmaceuticals Inc
Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.
Visit company website
5 years, 4 months ago
Pieris Pharmaceuticals, Inc is currently in a long term uptrend where the price is trading 34.2% above its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.1.
Pieris Pharmaceuticals, Inc's total revenue sank by 89.1% to $2M since the same quarter in the previous year.
Its net income has dropped by 1767.7% to $-14M since the same quarter in the previous year.
Finally, its free cash flow grew by 7.6% to $-14M since the same quarter in the previous year.
Based on the above factors, Pieris Pharmaceuticals, Inc gets an overall score of 3/5.